E-LIB Suche - Ergebnisse für: Giles, Francis J.

1

Efficacy and safety of bosutinib in patients treated with p..:

Smith, B. Douglas ; Brümmendorf, Tim H. ; Roboz, Gail J....
Leukemia Research. 139 (2024) - p. 107481 , 2024

Link: https://doi.org/10.1016/..

2

SLAM Modification as an Immune-Modulatory Therapeutic Appro..:

Tojjari, Alireza ; Giles, Francis J. ; Vilbert, Maysa..
Cancers. 15 (2023) 19 - p. 4808 , 2023

Link: https://doi.org/10.3390/..

3

GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immu..:

Huntington, Kelsey E. ; Louie, Anna D. ; Srinivasan, Praveen R....
International Journal of Molecular Sciences. 24 (2023) 13 - p. 10870 , 2023

Link: https://doi.org/10.3390/..

4

Impact of age and comorbidities on the efficacy and tolerab..:

Rosti, Gianantonio ; Brümmendorf, Tim H. ; Gjertsen, Björn T....
Leukemia. 38 (2023) 1 - p. 126-135 , 2023

Link: https://doi.org/10.1038/..

5

Clinical activity of 9-ING-41, a small molecule selective g..:

Hsu, Andrew ; Huntington, Kelsey E. ; De Souza, Andre...
Cancer Biology & Therapy. 23 (2022) 1 - p. 417-423 , 2022

Link: https://doi.org/10.1080/..

6

Dual inhibition of BET and HAT/p300 suppresses colorectal c..:

Kuang, Chaoyuan ; Tong, Jingshan ; Ermine, Kaylee...
Frontiers in Oncology. 12 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

7

Elraglusib (9-ING-41), a selective small-molecule inhibitor..:

Shaw, Gary ; Cavalcante, Ludimila ; Giles, Francis J..
Journal of Hematology & Oncology. 15 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

8

Human Metastatic Cholangiocarcinoma Patient-Derived Xenogra..:

Serra-Camprubí, Queralt ; Verdaguer, Helena ; Oliveros, Winona...
Clinical Cancer Research. 29 (2022) 2 - p. 432-445 , 2022

Link: https://doi.org/10.1158/..

9

Malignant glioma subset from actuate 1801: Phase I/II study..:

Odia, Yazmin ; Cavalcante, Ludimila ; Safran, Howard...
Neuro-Oncology Advances. 4 (2022) 1 - p. , 2022

Link: https://doi.org/10.1093/..

10

The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highl..:

van Gils, Noortje ; Martiañez Canales, Tania ; Vermue, Eline...
HemaSphere. 5 (2021) 8 - p. e610 , 2021

Link: https://doi.org/10.1097/..

11

Treatment-free remission following frontline nilotinib in p..:

Radich, Jerald P. ; Hochhaus, Andreas ; Masszi, Tamás...
Leukemia. 35 (2021) 5 - p. 1344-1355 , 2021

Link: https://doi.org/10.1038/..

12

Bromodomain and extra-terminal inhibitors—A consensus prior..:

Pearson, Andrew DJ. ; DuBois, Steven G. ; Buenger, Vickie...
European Journal of Cancer. 146 (2021) - p. 115-124 , 2021

Link: https://doi.org/10.1016/..

13

Moxetumomab pasudotox in heavily pre-treated patients with ..:

the Study 1053 investigators ; Kreitman, Robert J. ; Dearden, Claire...
Journal of Hematology & Oncology. 14 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

14

CTNI-13. MALIGNANT GLIOMA SUBSET FROM ACTUATE 1801 PHASE 1/..:

Odia, Yazmin ; Cavalcante, Ludimila ; Safran, Howard...
Neuro-Oncology. 23 (2021) Supplement_6 - p. vi61-vi62 , 2021

Link: https://doi.org/10.1093/..

15

Antitumor activity of the dual BET and CBP/EP300 inhibitor ..:

Spriano, Filippo ; Gaudio, Eugenio ; Cascione, Luciano...
Blood Advances. 4 (2020) 17 - p. 4124-4135 , 2020

Link: https://doi.org/10.1182/..